

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



MEMBERSHIP

May 29, 2026

Company name Shin Nippon Biomedical Laboratories, Ltd.
 Representative Representative Chairman, President & CEO
 Ryoichi Nagata
 Listing TSE PRIME : ticker code 2395
 Inquiries Honorary Executive Director, Head of IR &
 Corporate Communications, Toshiyuki Iwata
 TEL +81 3 5565 6216

Notice Regarding Distribution of Year-end Dividends from Retained Earnings

Shin Nippon Biomedical Laboratories, Ltd. (hereinafter, the “Company”) hereby announces that it was resolved at its Board of Directors’ meeting today that the dividends shall be paid from retained earnings to shareholders on the record date of March 31, 2026, as detailed below. As the result, together with the interim dividends already paid, the annual dividends for the fiscal year ended March 31, 2026, shall be ¥50.00 per share.

1. Details of year-end dividends

	Items resolved	Latest forecast (announced on May 11, 2026)	Dividends for the previous fiscal year ended March 31, 2025
Record date	March 31, 2026	Same as on the left	March 31, 2025
Dividend per share	¥30.00	Same as on the left	¥30.00
Total dividend payment	¥1,248 million	-	¥1,248 million
Effective date	June 29 2026	-	June 30, 2025
Dividend resource	Retained earnings	-	Retained earnings

2. Reasons for payment of dividends

The Company’s basic policy of stable profit distributions to shareholders, which is positioned as one of top management priorities, is to achieve the target of 30-40% in payout ratio on a consolidated basis, comprehensively considering Company’s earning capacity and cash flow position. Based on that and also on the belief that Company’s mainstay CRO business performed solidly, excluding the increased expenses related to business development for Satsuma’s Atzumi™, the Board of Directors decided upon the payment of the year-end dividends of ¥30.00 per share for the fiscal year ended March 31, 2026. That brings the annual dividends to ¥50.00 per share, together with the interim dividends already paid for the same fiscal year.

Additionally, as stated in “Consolidated Financial Results for the Fiscal Year Ended March 31, 2026 (Under Japanese GAAP)” announced on May 11, 2026, the Company expects its mainstay CRO business to achieve record high sales and operating profit and plans to continue paying the annual dividends of ¥50.00 per share for the fiscal year ending March 31, 2027, including the interim dividends of ¥20.00.

(Reference) Breakdown of annual dividends

	Dividends per share (¥: Japanese yen)		
	End of second quarter	Year-end	Total
Fiscal year ending March 31, 2027 (Forecast)	¥20.00	¥30.00	¥50.00
Fiscal year ended March 31, 2026	¥20.00	¥30.00	¥50.00
Fiscal year ended March 31, 2025	¥20.00	¥30.00	¥50.00

END